
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc is positioned positively due to its strategic amendments in the trial protocols that may allow for earlier intervention in neurodegenerative diseases, potentially enhancing the therapeutic benefits of its product PBFT02. The June 2025 interim data reinforces the robustness of PBFT02, showcasing sustained increases in crucial biomarkers such as CSF PGRN and plasma NfL, which are indicative of treatment efficacy and disease progression slowing. Furthermore, the possibility of regulatory alignment for accelerated approval based solely on biomarker endpoints could facilitate shorter trial timelines, thereby expediting the path to market and enhancing the company’s competitive edge in the genetic medicines sector.
Bears say
The analysis indicates a negative outlook on Passage Bio's stock primarily due to the inherent clinical risks associated with its gene therapy programs, which include potential delays in timelines and the emergence of safety concerns that could adversely affect market sentiment. Additionally, the company faces significant regulatory risks, as success in its clinical development of PBGM01 and PBFT02 may hinge upon the ability to navigate unforeseen safety issues or achieve anticipated efficacy levels. Furthermore, Passage Bio's operational outlook could be constrained if it and its partners fail to establish adequate manufacturing capacity, compounding the financial uncertainties surrounding its pipeline products designed to address rare, monogenic CNS disorders.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares